Breast Cancer is the most common cancer in women in India. 27.7% of all new cancers detected in women in India in the year 2018, were breast cancers.
One woman is diagnosed with
breast cancer, in India, every 4
*One woman dies of Breast
cancer, in India, every 8
ER/PR/HER2 only provide a superficial protein-based view of a tumor and not the underlying biology driivng its growth
Clinical factors onlye provide part of the story
MammaPrint + BluePrint guide adjuvent treatment decision making for patients with early stage Breast cancer
BluePrint, the 80-gene molecular subtyping assay, goes beyond the cell surface to evaluate the underlying biology of a tumor and what is driving its growth.
MammaPrint, the 70-gene breast cancer recurrence assay, is the first FDA-cleared and CE-marked risk-of-recurrence test backed by peer-reviewed, prospective outcome data and included in major treatment guidelines.
MP & BP offer a comprehensive genomic profile for the prediction of breast cancer recurrence risk & treatment selection (centrally analysed via microarray or locally via NGS).
MP & BP offer functional support in treatment decision-making & reduce uncertainty when choosing a treatment pathway for early stage breast cancer patients (both pre- & post-operative).
MP & BP can benefit early breast cancer patients (stage I, II, operable III, T<5cm, up to 3 lymph nodes) – clinicians can identify who needs chemotherapy and who can be spared its toxicity.
MINDACT+9 presents nearly 9 years of data from the MINDACT de-escalation trial* – an independent, randomized phase III clinical study for a breast cancer recurrence test
MINDACT - Microarray in Node- Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy
5-year DMFS for clinically high risk, genomically low-risk patients not treated with chemotherapy
ASCO recommends MamaPrint as the only test of its kind recommended to inform treatment decision for both lymph-node positive and lymph node negative breast cancer patients
|Test Code||Test Name||Technique||Speciment||Tat / Reported on|
|Molecular Array||Specimen - Formalin-fixed paraffin-embedded tissue block or 10 unstained slides with a 5 micron section on each slide. Must contain at least 30% invasive tumor.||18th Working Day|
|SMO10364||MammaPrint Assay||Molecular Array||10 unstained slides with a 5 micron section on each slide. Must contain at least 30% invasive tumor.||18th Working Day|